Last mentioned: Feb 20, 2026
Summit Therapeutics and its mid-cap biotech peers are set to report Q4 2025 results, with investor focus centered on Summit's ivonescimab commercialization path and BioMarin's Voxzogo expansion. These reports will serve as a critical barometer for the sector's ability to transition from R&D-heavy pipelines to sustainable commercial growth.
The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.
This page surfaces every story mentioning BioMarin Pharmaceutical across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where BioMarin Pharmaceutical was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |